Novo Nordisk Semaglutide Price Cut 2027: Wegovy & Ozempic List Price Drops to $675 Amid Eli Lilly Zepbound Competition Novo Nordisk announced that it will cut the U.S. list price of its leading semaglutide‑based medicines, Wegovy, Ozempic, and Rybelsus, to $675 per month starting January 2027, marking a significant step to improve affordability and access to GLP‑1 therapies for obesity and type 2 diabetes The price reduction, representing up to 50% off for Wegovy and 35% for
